

McDermott Will & Emery

RECEIVED
CENTRAL FAX CENTER
JAN 05 2007

Boston Brussels Chicago Düsseldorf London Los Angeles Miami Milan
Munich New York Orange County Rome San Diego Silicon Valley Washington, D.C.

FACSIMILE

Date: January 5, 2007

Time Sent:

To:	Company:	Facsimile No:	Telephone No:
Mail Stop: AMENDMENT	USPTO	571-273-8300	
From:	Atabak R. Royaee	<i>Direct Phone:</i>	617.535.4108
E-Mail:	aroyaee@mwe.com		
Sent By:		<i>Direct Phone:</i>	
Client/Matter/Tkpr:	068911-0030	<i>Original to Follow by Mail</i>	No
		<i>Number of Pages, Including Cover:</i>	13

Message:

BST99 1525996-1.068911.0060

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copy of this facsimile is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone and return the original message to us at the below address by mail. Thank you.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL AS SOON AS POSSIBLE.

Main Facsimile: 617.535.3800 Facsimile Operator: 617.535.4000

U.S. practice conducted through McDermott Will & Emery
28 State Street Boston, Massachusetts 02109-1775 Telephone: 617.535.4000

PAGE 1/13 * RCVD AT 1/5/2007 2:08:47 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/45 * DNIS:2738300 * CSID:617 535 3869 * DURATION (mm:ss):04:28

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
RECEIVED
CENTRAL FAX CENTER


In re Application of: Babish, John G., et al.
 Application No.: 09/885,721
 Filing Date: June 20, 2001
 Docket Number: 068911-0030
 Title: COMPLEX MIXTURES EXHIBITING SELECTIVE INHIBITION OF CYCLOOXYGENASE-2
 Examiner: Michael V. Meller
 Art Unit: 1655
 Confirmation No.: 3304

JAN 05 2007

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Mail Stop: Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571-273-8300) to the USPTO, on the date indicated below.

Date: January 5, 2007



Jacqueline Andrew
Jacqueline Andrew

MAIL STOP AMENDMENT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Sir:

Enclosed herewith for filing in connection with the above-identified patent application are the following:

- 1) Amendment After Allowance (11 pages)

There are no fees due with the filing of this Amendment. However, the Commissioner is authorized to charge any further fees which may become due and/or credit any overpayment to Deposit Account Number 50-1133

Respectfully submitted,



Atabak R. Royaei, Reg. No. 59,037
 McDERMOTT WILL & EMERY LLP
 28 State Street
 Boston, Massachusetts 02109
 Telephone: (617) 535-4108
 Facsimile: (617) 535-3800

Dated: January 5, 2007

00T99 1527946-1.068911.0030

JAN 05 2007

PATENT
Attorney Docket No. 068911.0030

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Group Art Unit: 1655
Babish, John G. et al.)
Application No.: 09/885,721) Examiner: Meller, M.
Filed: June 20, 2001) Notice of Allowance Dated: 12/05/2006
For: COMPLEX MIXTURES) Confirmation No.: 3304
EXHIBITING SELECTIVE)
INHIBITION OF)
CYCLOOXYGENASE-2)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

AMENDMENT AFTER ALLOWANCE

This paper is in response to the Notice of Allowance dated December 05, 2006, in the above-identified patent application. In that Notice of Allowance, all pending claims 1, 6-8, and 52-54 have been allowed. Pursuant to 37 C.F.R. § 1.312 and subject to the recommendation of the Examiner and the approval of the Director, and without withdrawing the case from issue, kindly amend the above-identified application as follows:

Amendments to the Specification are included in this paper at page 2.

Amendments to the Claims are reflected in the listing of claims in this paper at page 9.

Remarks follow the amendment sections of this paper at page 11.